Stryker stock gains after a revenue beat and higher guidance
Published on 09/07/2026 at 23:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Stryker Corp. stock (ISIN US8636671013) is trading with the latest quarter as the main driver: revenue reached USD 6.59 billion, up 9.4 percent year over year, while adjusted EPS came in at USD 3.69 and beat the consensus estimate of USD 3.49 by USD 0.20.
The same update also lifted full-year 2026 EPS guidance to USD 14.95 to USD 15.10, a range that frames the rest of the year for the medical technology group. MarketBeat reported the figures on September 7, 2026, and the same report says analysts now expect USD 15.03 EPS for the current fiscal year.
Revenue and earnings set the tone
The quarter gives investors three concrete markers: USD 6.59 billion in revenue, USD 3.69 EPS and guidance of USD 14.95 to USD 15.10 for fiscal 2026. Against the prior-year quarter's USD 3.13 EPS, the latest number shows a clear year-over-year step up, and the revenue growth rate of 9.4 percent underlines that operating momentum is not limited to one line item.
For the stock, the key question is how far the guidance range can be sustained through the next reporting cycle. The consensus figure of USD 15.03 EPS sits close to the company's own outlook and leaves little room for a large surprise unless margins or volumes improve further.
Analysts still see support
MarketBeat also says Stryker carries a consensus rating of Moderate Buy with an average price target of USD 386.28. That creates a broad gap between the current earnings setup and the market's longer-term expectations, even though the near-term driver remains the latest quarter rather than any fresh corporate action.
A second data point in the same update is the quarterly dividend of USD 0.88, with investors of record on September 30, 2026 and payment planned for October 30, 2026. The dividend adds a steady capital-return element to a quarter otherwise defined by operating outperformance.
Product lines and investor focus
Stryker's medical technology franchise spans surgical equipment, orthopedic implants and hospital systems, which is why revenue growth of 9.4 percent matters more than a single product headline. The latest quarter shows that demand is broad enough to support both earnings and guidance at the same time.
Trading picture
Company: Stryker Corp.
ISIN: US8636671013
Ticker: SYK
Trading venue: NYSE
Sector / Industry: Health Care / Medical Devices
Index membership: S&P 500
Price (as of September 7, 2026): not available in the search results
Market capitalization: not available in the search results
Next earnings date: not available in the search results
